Personalized Treatment of Urogenital Cancers Depends on the Microbiome

Zealand University Hospital

Status: Enrolling

Conditions: Microbial Disease

Treatments: Other: Placebo; Drug: Tigecycline 50 MG

Study type: Interventional

Funder types: Other

Identifiers

NCT03962920

ZUHURO

Details and patient eligibility

About

This is a randomized controlled trial where patients undergoing surgical treatment for urogenital cancers will be randomized in a two arms study: surgical treatment + antibiotics OR surgical treatment + placebo.

Enrollment: 28 estimated patients

Sex: All

Ages: 40 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Biopsy verified diagnosis of urological cancer, localized disease

Exclusion criteria

• Hospitalization within three months of surgery
• Antibiotics within three months of surgery
• Infectious disease, including UTI's within three months of surgery
• History of cancers of the genitourinary tract
• Diabetes

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

28 participants in 2 patient groups, including a placebo group

Surgical treatment + antibiotics

Active Comparator group

Description:

Use antibiotic

Treatment:

Drug: Tigecycline 50 MG

surgical treatment + placebo

Placebo Comparator group

Description:

Use placebo

Treatment:

Other: Placebo